interstitial lung diseases, lung transplant tissue, and COVID-19 lung tissue
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: - Histological Tissue • Histopathologically diagnosed interstitial lung disease, lung transplant tissue, or COVID-19 autopsy cases (positive control: altered lung parenchyma of the affected lung lobes / negative control: non-altered lung parenchyma of the unaffected lung lobes of the same patients) - Biological Samples • Presence of signed informed consent from the Thorax Biobank Heidelberg or the Hannover Unified Biobank (HUB) - Radiological and Clinical Data • Radiologically or clinically diagnosed interstitial lung disease, lung transplantations, or COVID-19 cases.
Exclusion criteria
Exclusion criteria: - Histological Tissue • Routine diagnostics have not yet been completed. • Reuse of the tissue for future diagnostic procedures cannot be excluded. • No biomaterial available or insufficient biomaterial available. - Biological Samples • Withdrawal of informed consent. - Radiological and Clinical Data • Routine diagnostics have not yet been completed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the study is to identify microvascular and pericyte alterations in histological tissue from patients with interstitial lung disease (ILD) and to establish them as novel diagnostic markers for routine histopathological assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives include the identification of diagnostically relevant vascular and angiogenesis-related protein expression patterns, as well as the correlation of histological, clinical, and radiological data sets. | — |
Countries
Germany
Contacts
Pathologisches Institut